Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors

被引：0
|
作者：
Siu, Lillian L.
Gil-Martin, Marta
Cho, Byoung Chul
Perets, Ruth
Hilton, John
Geva, Ravit
Lugowska, Iwona
Gutierrez, Martin
Bonomi, Marcelo
Dziadziuszko, Rafal
Rasco, Drew
Ben-Ami, Eytan
Rodriguez, Cristina P.
Siddiqi, Shabana
Myer, Nicole
Suttner, Leah
Wilson, Douglas
Akala, Ombololaji O.
de Miguel, Maria
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT104
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of the anti-immunoglobulin-like transcript 4 ( ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non- small cell lung cancer (NSCLC)
    Cho, Byoung Chul
    Hilton, John
    Rodriguez, Cristina P.
    Bonomi, Marcelo
    Siu, Lillian L.
    Gil-Martin, Marta
    Siddiqi, Shabana
    Myer, Nicole M.
    Suttner, Leah
    Wilson, Douglas
    Akala, Omobolaji
    Dziadziuszko, Rafal
    CANCER RESEARCH, 2024, 84 (07)
  • [2] Initial results of a phase I study of MK-4830, a first-in-class anti-immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
    Siu, L. L.
    Wang, D.
    Hilton, J.
    Geva, R.
    Rasco, D.
    Abraham, A. K.
    Markensohn, J. F.
    Suttner, L.
    Siddiqi, S.
    Altura, R. A.
    Maurice-Dror, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S462 - S462
  • [3] A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti-immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer
    Lee, Jung-Yun
    Bell, Maria
    Bidzinski, Mariusz
    Bodnar, Lubomir
    Chan, Jack Junjie
    Gill-Martin, Marta
    Ibanez, Carolina
    Lorusso, Domenica
    Lu, Chien-Hsing
    Rosengarten, Ora
    Townson, Steven M.
    Kobie, Julie
    Zhang, Yiwei
    Pruitt, Scott
    Shapira-Frommer, Ronnie
    CANCER RESEARCH, 2023, 83 (08)
  • [4] First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
    Siu, Lillian L.
    Wang, Ding
    Hilton, John
    Geva, Ravit
    Rasco, Drew
    Perets, Ruth
    Abraham, Anson K.
    Wilson, Douglas C.
    Markensohn, Julia F.
    Lunceford, Jared
    Suttner, Leah
    Siddiqi, Shabana
    Altura, Rachel A.
    Maurice-Dror, Corinne
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 57 - 70
  • [5] First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (vol 28, pg 57, 2022)
    Siu, Lillian L.
    Wang, Ding
    Hilton, John
    Geva, Ravit
    Rasco, Drew
    Perets, Ruth
    Abraham, Anson K.
    Wilson, Douglas C.
    Markensohn, Julia F.
    Lunceford, Jared
    Suttner, Leah
    Siddiqi, Shabana
    Altura, Rachel A.
    Maurice-Dror, Corinne
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 4158 - 4158
  • [6] First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (vol 28, pg 57, 2022)
    Siu, Lillian L.
    Wang, Ding
    Hilton, John
    Geva, Ravit
    Rasco, Drew
    Perets, Ruth
    Abraham, Anson K.
    Wilson, Douglas C.
    Markensohn, Julia F.
    Lunceford, Jared
    Suttner, Leah
    Siddiqi, Shabana
    Altura, Rachel A.
    Maurice-Dror, Corinne
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1734 - 1734
  • [7] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482+pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM)
    Kim, Tae Min
    Kim, Sang-We
    Gutierrez, Martin
    Di Giacomo, Anna Maria
    Voskoboynik, Mark
    Myer, Nicole
    Edmondson, Mackenzie
    Liu, Qi
    Chen, Mei
    Victoria, Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482+pembrolizumab plus gemcitabine plus nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Golan, Talia
    Cohen, Jonathan
    Voskoboynik, Mark
    Gutierrez, Martin
    Park, John J.
    Valente, Monica
    Renouf, Daniel John
    Liu, Qi
    Edmondson, Mackenzie
    Myer, Nicole
    Kapadia, Kishan J.
    Chen, Mei
    Victoria, Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [10] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
12345